Abstract
BACKGROUND: Resistance of microorganisms to antimicrobial drugs (AMP) is one of the global problems of modern medicine, which poses a serious threat to human health. The formation of the resistance of pathogens to AMP forces us to look for new ways to combat them. Probiotic therapy is one of the promising and safe methods of treating many infectious diseases.
AIM: This study assesses the sensitivity of clinical strains of pathogenic and opportunistic bacteria and fungi to microorganisms that are part of probiotic preparations.
MATERIALS AND METHODS: The sensitivity of 93 cultures of pathogenic and opportunistic microorganisms (UPM) isolated from the feces of patients with intestinal dysbiosis to strains of probiotic bacteria isolated from commercial probiotic preparations was studied: Lactobacillus plantarum 8RA-3, Escherichia coli M-17, Bacillus subtilis strain VKPM B-10641, Enterococcus faecium SF-68, Saccharomyces boulardii CNCM I-745 by the delayed antagonism method.
RESULTS: Pathogenic microorganisms showed low and moderate sensitivity to the probiotic strain of L. plantarum. Sensitivity to the probiotic strain of B. subtilis was detected in Staphylococcus aureus strains, low or completely absent in Pseudomonas aeruginosa, Klebsiella spp., Serratia marcescens. The most sensitive to the probiotic strain were clinical strains of E. coli.
CONCLUSION: UPM and pathogenic microorganisms isolated from the gastrointestinal tract of patients with dysbiosis have different sensitivity to probiotic strains: from high to several probiotics to its complete absence. The empirical approach to prescribing a probiotic does not guarantee a therapeutic effect, which makes it prudent to individualize the selection of a probiotic based on an assessment of its antimicrobial activity against isolated pathogens.
Subject
Building and Construction